AKT1 and melanoma: Treatment with lapatinib was demonstrated to significantly reduce cell growth in ERBB4-mutant melanoma cells lines at 10- to 250- fold higher sensitivity (IC50) than ERBB4 WT cells, resulting in dose-dependent inhibition of ERBB4 auto-phosphorylation and downstream Akt signalling.